CER Daily Newsfeed

Indirect Comparison Finds Zanubrutinib Associated With Better PFS, OS Than Acalabrutinib in MCL

(9/12, Mary Caffrey, The American Journal of Managed Care) reports “...An analysis based on separate trials of the Bruton tyrosine kinase (BTK) inhibitors zanubrutinib (Brukinsa; BeOne Medicines) and acalabrutinib (Calquence; AstraZeneca) found that zanubrutinib was associated with ‘significantly improved’ progression-free survival (PFS) and overall survival (OS) for patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), according to results published in Leukemia & Lymphoma.” Full

Leveraging Real-World Evidence to Advance Pain Research

(9/12, Lisa Kuhns, PhD, Clinical Pain Advisor) reports “Real-world evidence (RWE) derived from real-world data (RWD) has the potential to complement randomized clinical trials (RCTs) and advance pain research, but rigorous design, analysis, and reporting standards are essential to ensure validity and credibility, according to study results published in Pain.” Full

From Real-World Evidence To Digital Quality: Why Life Sciences Needs Integrated Solutions

(9/12, Rahul Saluja, Forbes) comments “...The rise of cloud, AI and automation has made integration more achievable than ever. Advanced analytics platforms can mine RWE at scale, uncovering predictive insights. Digital quality systems ensure compliance is built into processes rather than layered on top as an afterthought. Internet of Things (IoT) in manufacturing provides real-time visibility, linking operational efficiency directly to product availability and patient safety. When these elements come together, the results are tangible: reduced trial timelines, accelerated submissions, improved manufacturing efficiency and therapies reaching patients faster.” Full